Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

News Features

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

Michael O'Riordan

December 09, 2019

Presentation TCT 2019

The Evolving SYNERGY Programs: EVOLVE-Short DAPT Updates

Presenter: Ajay Kirtane

September 28, 2019

Presentation TCT 2019

Short and Optimal DAPT: Lessons From the EVOLVE SHORT-DAPT Late Breaking Science

Presenter: Ajay Kirtane

September 27, 2019

Presentation TCT 2019

EVOLVE/ LEADERS Short DAPT Programs

Presenter: Ajay Kirtane

September 27, 2019

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

Caitlin E. Cox

September 26, 2019

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

Shelley Wood

September 26, 2019

Presentation TCT 2019

EVOLVE Short DAPT: A Single-Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated With a Bioabsorbable Polymer-Based Everolimus-Eluting Stent

Presenter: Ajay Kirtane

September 26, 2019

News Opinion Fellow Talk

What I Am Most Looking Forward to at TCT 2019

Mahesh V. Madhavan, MD

September 18, 2019

News Daily News

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

Michael O'Riordan

July 03, 2019

News Conference News SCAI 2019

Cancer and CV Disease Care: What’s Known? What Lies Ahead for Cardio-Oncology?

Yael L. Maxwell

May 30, 2019

Partner Content

SYNERGY-BP-DES-Optimizing Antiplatelet Therapy After PCI in Complex and High Bleeding Risk Patients - Boston Scientific

November 15, 2019

Video

» Interview

Dr. C. Michael Gibson Talks With Dr. Ajay Kirtane About EVOLVE Short DAPT: A Single Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated a Bioabsorbable Polymer-Based Everolimus-Eluting Stent

September 29, 2019

Advertisement

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

The Evolving SYNERGY Programs: EVOLVE-Short DAPT Updates

Short and Optimal DAPT: Lessons From the EVOLVE SHORT-DAPT Late Breaking Science

EVOLVE/ LEADERS Short DAPT Programs

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

EVOLVE Short DAPT: A Single-Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated With a Bioabsorbable Polymer-Based Everolimus-Eluting Stent

What I Am Most Looking Forward to at TCT 2019

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

Cancer and CV Disease Care: What’s Known? What Lies Ahead for Cardio-Oncology?

SYNERGY-BP-DES-Optimizing Antiplatelet Therapy After PCI in Complex and High Bleeding Risk Patients - Boston Scientific

Dr. C. Michael Gibson Talks With Dr. Ajay Kirtane About EVOLVE Short DAPT: A Single Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated a Bioabsorbable Polymer-Based Everolimus-Eluting Stent

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content